Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Gene Linked to Poor Prognosis for Melanoma

By Labmedica International staff writers
Posted on 06 Mar 2013
A gene has been identified that is present in some patients with melanoma, which appears to make the tumor cells more resistant to treatment.

The gene, Tumor protein p63 (TP63), is unexpectedly expressed in a number of melanoma cases and correlates significantly with a worse prognosis and it is hoped this new understanding of what makes some melanoma cells so difficult to kill will help the development of new therapies.

Scientists at Queen Mary, University of London (UK) analyzed 156 melanoma tissue samples from 129 individuals for expression of the protein p63, which is encoded by the gene TP63. Overall, 19 recurrent melanoma samples and 56 metastatic melanoma tumor samples from 49 individuals, 22 males and 27 females, were analyzed. The median age at diagnosis was 60.6 years and the median follow up for this cohort was 1.52 years. The proportion of p63-positive tumors comprised 10/19 (53%) of recurrent tumors and 37/56 (66%) of metastatic tumors.

Overall mortality for recurrent and metastatic tumors was 45% and melanoma-specific mortality was 37%. Median age of death was 62.4 years with median time to death from first recurrence or metastases was 15 months. The number of cases of melanoma is rising faster than almost any other cancer and one of the main risk factors is ultraviolet light, which comes from the sun or sun beds [tanning bed]. While early-stage melanomas can often be removed by surgery, more advanced melanomas are much harder to treat.

Daniele Bergamaschi, PhD, a senior lecturer in cutaneous research at Queen Mary said, "For most patients where the melanoma has spread beyond the skin, there are few effective treatments and overall survival rates for this disease have not changed much over the past 30 years. To develop better treatments we need to understand the basic biology underpinning why these cells are so resistant to being killed."

Dr. Bergamaschi added, "We did not expect to find the TP63 gene expressed in melanoma. It is not usually found in the melanocytes (skin pigment cells), which are the cells from which melanomas develop. However, it appears in some cases this gene is turned on as the tumor forms, and when it does it is linked to a worse prognosis." The study was published on February 18, 2013, in the Journal of Experimental Medicine.

Related Links:
Queen Mary, University of London



KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
Dubai Bio Expo-2015

Channels

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.